drugset / Trial / NCT00660309

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

NCT00660309

Phase 4 Completed 45 enrolled Novartis
RandomizedParallel-groupOpen-label

Summary

The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or irbesartan on renal blood flow, glomerular filtration rate, and retinal blood flow in patients with type 2 diabetes mellitus.

Timeline

Start
2008-04
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg Oral
Subject Captopril Small molecule 25 mg Oral
Comparator Irbesartan Small molecule 300 mg Oral